ATHERO-FLUX

Athero-Flux builds on cutting-edge SME-led biotechnological tools including: a) high-throughput lipidomic platforms that allow the study of kinetics of lipid metabolism at the molecular lipid level including the new stable isotope labelling technique (Flux); b) whole genome RNA interference screening tools that will allow to identify the regulators of the production of SLs and the mediators of their biological effect; c) unique locked nucleotide antagonist platforms that have been successfully used clinically in more than 300 patients worldwide. The identification and the validation of the best targets to abate SL metabolism though a combination of SME-based leading technology and academia modeling has a strong potential for development of new lipid lowering therapeutics to abate previously unrecognized risk factors for CVD... Targeting novel lipid pathways for treatment of cardiovascular disease

Primary location: Oxford United Kingdom